News and Views
Nature Biotechnology 27, 821 - 823 (2009)
doi:10.1038/nbt0909-821
Silencing prostate cancer
Ivanka Toudjarska1 & Antonin de Fougerolles1
- Ivanka Toudjarska and Antonin de Fougerolles are at Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.
Correspondence to: Antonin de Fougerolles1 e-mail: tdefougerolles@alnylam.com
Abstract
Systemic delivery of an siRNA–aptamer chimera leads to prostate cancer regression in mice.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumorsNature Biotechnology Research (01 Sep 2009)
Cell type?specific delivery of siRNAs with aptamer-siRNA chimerasNature Biotechnology Research (01 Aug 2006)
Novel Dual Inhibitory Function Aptamer?siRNA Delivery System for HIV-1 TherapyMolecular Therapy Original Article


